Marku Santonen, before becoming General Manager of Amgen’s Nordic and Baltic division, worked with some of the biggest names in the industry. Most notably as Marketing…
In Conversation
Could you begin by introducing Diamyd Medical and therapeutic focus to those of our international readership that are not yet familiar with your name? Diamyd was…
Could you begin by giving a short introduction to Nordic Drugs and its current position within the structure of owner Nordic Group? Nordic Drugs started as…
As the blockbuster sales model fades, the rush is on for a new formula for growth, termed ‘Good growth’ by Pharmaceutical Executive: niched, balanced & sustainable…
You refer to AstraZeneca as the locomotive of bioscience in Sweden. Can you elaborate on what you mean by that, and the role that you see…
Last year, Boston Scientific took important steps to stabilise and strengthen its core businesses. Could you develop on the development trajectory of Boston Scientific in the…
There seems to be quite a hype around the Nordic region at the moment. How do you explain this phenomenon? I think that the Nordic region…
Mary Di Marzio has been General Manager of Nordics for Shire Inc for nearly 2 years now. Today she shares with Pharmaboardroom the progress of Shire’s…
